Kratom Research Institute

Safety · 2026-05-21

MGM-15: A New Semi-Synthetic Kratom-Derived Opioid Compound Is Emerging in Smoke Shops and Online Markets

Source: Brooks Healing Center

Why it matters

As regulators crack down on 7-OH, a newer kratom-derived compound called MGM-15 is emerging in consumer markets — with strong opioid receptor activity, almost no human safety data, and the ability to evade standard drug tests.

The big picture

The kratom derivative market continues to evolve faster than regulators can respond. MGM-15 (dihydro-7-hydroxymitragynine, also called DHM or DH-7OH-MIT) is a chemically modified compound related to 7-OH. Catalogued by both the United Nations Office on Drugs and Crime and the Center for Forensic Science Research and Education, it is now appearing in tablets, capsules, gummies, and liquid shots at smoke shops and online retailers. A 2025 peer-reviewed study in Drug Testing and Analysis (Gour et al.) formally identified it as a compound of concern.

Key findings

What they say

"A product does not have to come from a pharmacy or street dealer to create dependence. If it acts on opioid receptors and becomes hard to stop, it deserves to be taken seriously." — Brooks Healing Center clinical team, May 2026

Bottom line

MGM-15 is the next compound in a rapidly evolving market of kratom-derived semi-synthetic opioids — emerging commercially at the same moment that federal and state regulators are still catching up to 7-OH.